偏头痛患者对抗CGRP单克隆抗体的延迟应答:一项多中心前瞻性观察性研究
这项多中心前瞻性真实世界研究纳入771例接受抗CGRP单克隆抗体治疗至少24周的高频或慢性偏头痛成人患者,评估12周后延迟应答的频率与特征。12周时应答者为65.6%(506/771),非应答者为34.4%(265/771),其中55.1%(146/265)随后出现应答。作者认为抗CGRP单克隆抗体的疗效应在24周评估,治疗时长应延长至12个月以上。
要点
- 12周时非应答者中约半数(55.1%,146/265)在后续出现延迟应答。
- 延迟应答者与12周应答者相比BMI更高、既往治疗失败更多、精神共病更多。
- 延迟应答者单侧疼痛、单侧颅自主神经症状及异常性疼痛较少见。
核心结论
- 12周时抗CGRP单克隆抗体的非应答者中有一半实际上是延迟应答者,疗效应在24周评估,治疗时长应延长至12个月以上。
研究设计与样本
- 多中心(n=16)前瞻性真实世界研究,连续纳入接受抗CGRP单克隆抗体治疗至少24周的高频或慢性偏头痛成人患者。
主要发现
- 771例完成至少24周治疗,12周应答者为65.6%(506/771),非应答者为34.4%(265/771)。
- 265例12周非应答者中146例(55.1%)随后出现应答(延迟应答者)。
- 延迟应答者与应答者相比BMI更高(+0.78,95% CI [0.10; 1.45];p=0.024)。
- 延迟应答者与应答者相比治疗失败次数更多(+0.52,95% CI [0.09; 0.95];p=0.017)、精神共病更多(+10.1%,95% CI [0.1; 0.20];p=0.041)。
关键数值与推荐
- 应答者定义为第9-12周每月偏头痛/头痛天数较基线减少≥50%。
- 延迟应答者定义为仅在12周之后才达到≥50%减少的患者。
临床怎么用
- 作者认为抗CGRP单克隆抗体的疗效应在24周评估,治疗时长应延长至12个月以上。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the frequency and characteristics of late responders (>12 weeks) to monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP). METHODS: This is a multicenter (n = 16) prospective real-life study considering all consecutive adults with high-frequency or chronic migraine treated with anti-CGRP mAbs for ≥24 weeks. We defined responder patients with a ≥50% reduction from baseline in monthly migraine/headache days at weeks 9-12 and late responders as those achieving a ≥50% reduction only afterward. RESULTS: A total of 771 people with migraine completed ≥24 weeks of anti-CGRP mAb treatment. Responders at 12 weeks were 65.6% (506/771) of the patients, while nonresponders were 34.4% (265/771). A total of 146 of the 265 nonresponders (55.1%) at 12 weeks responded afterward (late responders): they differed from responders for a higher BMI (+0.78, 95% CI [0.10; 1.45]; p = 0.024), more frequent treatment failures (+0.52, 95% CI [0.09; 0.95]; p = 0.017) and psychiatric comorbidities (+10.1%, 95% CI [0.1; 0.20]; p = 0.041), and less common unilateral pain, alone (-10,9%, 95% CI [-20.5; -1.2]; p = 0.025) or in combination with unilateral cranial autonomic symptoms (-12.3%, 95% CI [-20.2;-3.9]; p = 0.006) or allodynia (-10.7, 95% CI [-18.2; -3.2]; p = 0.01). DISCUSSION: Half of nonresponders to anti-CGRP mAbs at 12 weeks are indeed late responders. Efficacy of anti-CGRP mAbs should be assessed at 24 weeks while treatment duration should be extended beyond 12 months.
引用
- Barbanti P, Aurilia C, Egeo G, et al. Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter Prospective Observational Study. Neurology. 2023. PMID: 37072224. doi:10.1212/WNL.0000000000207292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。